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Noroviruses (NoV) are single-stranded RNA, non enveloped viruses belonging to the family 
of the Caliciviridae . The genus NoV has been separated in five genogroups, designated GI 
through GV. Three of these, namely GI, II and IV, are pathogenic to humans. Each 
genogroup contains several genotypes. A single genotype, GII.4, is associated with the 
majority of global outbreaks. Within the last years, several NoV outbreaks occurred and were 
documented in Belgium hospitals. 
 
After an average incubation from 12 to 48 hours, NoV illness is characterized by acute-onset 
vomiting, watery non-bloody diarrhoea with abdominal cramps, and nausea. Recovery is 
usually complete after 2 or 3 days. However, more prolonged courses of illness and viruses 
shedding can occur, particularly among young children, elderly persons and hospitalized 
patients.  
 
NoV are transmitted primarily through the fecal-oral route, either by direct person-to-person 
spread or fecally contaminated food or water. NoV can also spread via a droplet route from 
vomitus.  
 
NoV are now recognized as the leading cause of epidemics of gastroenteritis, and represent 
an important cause of sporadic gastroenteritis in both children and adults.  
The characteristics of NoV facilitate their spread during outbreaks: NoV are highly 
contagious; these viruses are relatively stable in the environment and can survive freezing 
and heating to 60°C; shedding may last several week s; carrier may be asymptomatic; no or 
limited long-term immunity results from infection. 
 
Diagnosis of NoV infection relies on the detection of viral RNA in the stools of affected 
persons, by use of reverse transcription-polymerase chain reaction (RT-PCR) assays. 
Sequencing of NoV strains found in clinical and environmental samples greatly helps in 
conducting epidemiologic investigations.  
Commercial enzyme-linked immunoassays detecting NoV antigen currently exhibit 
inadequate sensitivity (<50%) to be useful for diagnosis of sporadic cases. However, in 
outbreak settings, these tests may be useful to rapidly identify NoV as the likely aetiology. 
Because of the limited availability of timely and routine laboratory diagnostic methods, a 
clinical diagnosis of NoV infection is often used. The Outbreak Kaplan Criteria are very 
specific—when all four criteria are present, there is a high likelihood that the outbreak is 
attributable to NoV.  
 
There is no specific drug to treat people with NoV infection. Symptomatic therapy consists of 
replacing fluid losses and correcting electrolyte disturbances. No vaccine is available.  
 
In Belgium, the Superior Health Council recommends to apply general precautions in our 
daily practice. Appropriate hand hygiene is likely the most important method to prevent NoV 
infection and control transmission. Ethanol-based hand sanitizers (≥62% ethanol) may be 
 2
helpful as an adjunct method of hand hygiene, but should not replace washing with soap and 
water. 
 
In case of hospital outbreak, the Belgian Superior Health Council advises to implement 
additional contact (and droplets if needed) precautions. Several key approaches to interrupt 
NoV spread followed by most of European countries are fully described by the Centers for 
Disease Control and Prevention (USA). They consist mainly in managing patients with 
suspected NoV infection with careful attention to hand hygiene practice, cleaning and 
disinfecting the contaminated environmental surfaces. Strict control measures, including 
isolation or cohorting of symptomatic patients, exclusion of affected staff, and restricting new 
admissions in affected units are disruptive and costly but might be required to curtail 
outbreaks. 
 
Therefore, in front of a gastroenteritis outbreak, think norovirus, as it has a considerable 
public health impact. It is important to diagnose rapidly a beginning NoV outbreak in order to 
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